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ABSTrACT
Objectives: We examined the impact of continuous subcutaneous insulin infusion (CSII) and continuous glucose moni-
toring systems (CGM) during pregnancy in women with pre-gestational type 1 diabetes (T1DM) on glycemic control and 
subsequent adverse outcomes. 
Material and methods: In this observational, one-center study we analyzed records of consecutive 109 T1DM pregnancies 
(2016–2017). The final analyzed group consisted of 81 singleton pregnancies who met inclusion and exclusion criteria. We 
searched for the association between the use of CSII with or without CGM and pregnancy planning with glycated hemo-
globin A1c (HbA1c) through pregnancy and after delivery as well as maternal and infant outcomes. 
results: Patients using CSII and CGM vs CSII without CGM and MDI (multiple daily injections) users had the lowest HbA1c 
levels during and after pregnancy (5.3%, 5.3%, 5.2% and 5,5% in the 1st, 2nd, 3rd trimester and postpartum visit, p = 0.003, 
p = 0.030, p = 0.039 and p = 0.002, respectively). Patients treated with insulin pumps with CGM and additional functions 
of automatic insulin delivery suspension on low glucose level (SLG) or predictive low glucose suspend (PLGS) during the 
third trimester and after pregnancy achieved a significantly lower HbA1c than the other CSII patients. We did not find 
any differences between the study groups in gestational age at delivery, preterm births, birth weight or macrosomia risk. 
Despite very good glycemic control, the risk of macrosomia remained high (19.7%). 
Conclusions: The use of pumps equipped with CGM, especially with automatic insulin delivery suspension, may improve 
glycemic control in pregnant T1DM women. The proportion of macrosomia remained high. 
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InTrOduCTIOn
Maintaining target glucose and glycated hemoglobin 
A1c (HbA1c) levels in normoglycemic states while pregnant 
with diabetes type 1 is essential to reduce the risk of fetal 
hyperglycemia exposure. During this same period, it is also 
important to limit maternal hypoglycemic episodes. Both 
objectives are considered critical to reducing the risk of poor 
outcomes in both mother and neonate [1, 2]. 
However, the burden of macrosomia in pregnancies 
in women with pre-gestational type 1 diabetes (T1DM) 
remains still higher compared to the general population, 
despite in-target or near-target glycemic control and the 
risk of macrosomia remained glucose-dependent [3]. 
The high risk of macrosomia for in-target (< 6.0%) hemo-
globin A1c (HbA1c) may be driven by hyperglycemic spikes 
missed in routine self-monitoring of blood glucose (SMBG) 
performed with a glucose meter.
Inadequate blood glucose management during preg-
nancy was linked not only to macrosomia but also to other 
adverse pregnancy outcomes in mothers and infants. These 
risks were extended to potential obesity, diabetes and car-
diovascular disease later in child’s life [4–6]. Approximately 
half of the pregnant women with diabetes in the United 
Kingdom do not reach their HbA1c targets [7]. The improve-
ment of pre-pregnancy care and the promotion of preg-
nancy planning may be adequate and effective. However, 
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a new challenge emerges for the women reaching the rec-
ommended glycemic target.
Continuous glucose monitoring systems (CGM) are 
becoming more widespread in recent years. They offer 
a complete, 24-hour glucose profile capturing all blood 
glucose fluctuations. The measurement takes place in the 
subcutaneous tissue with a reduced need for fingerstick 
calibration, where rapid changes in glucose concentration 
mirror the changes in the blood. Modern personal insulin 
pumps augmented with CGM sensors with functions like 
automatic insulin delivery suspension on low glucose level 
(SLG) or predictive low glucose suspend (PLGS) offer ad-
ditional benefits for their users. In a cost-utility analysis 
performed in Sweden, it was concluded that the use of a SLG 
pump was effective in T1DM patients with poorly controlled 
diabetes and in those with a high risk of hypoglycemia [8]. 
A recent CONCEPTT study found that the prolonged use 
of CGM through pregnancy in women with pregestational 
T1DM resulted in the reduction in HbA1c, more time spent 
within target glucose levels, less time spent above the target 
and reduced glycemic variability [9]. Such improvements 
translated into better neonatal outcomes, particularly in the 
lower incidence of macrosomia and neonatal hypoglycemia.
The use of CGM and sensor-augmented insulin pumps 
are becoming a standard of care in pregnant women with 
T1DM [10, 11]. Here, we report our initial experience with 
the use of CGM in pregnant T1DM women in the Lesser 
Poland region.
Objectives
Our aim was to examine the impact of the use of CGM 
and continuous subcutaneous insulin infusion (CSII) on 
glycemic control and the risk of maternal and infant adverse 
outcomes as compared to MDI during pregnancy in women 
with pre-gestational T1DM. 
MATerIAL And MeThOdS
This study was performed at the Clinical Department 
of Metabolic Diseases, University Hospital in Krakow, Po-
land, a tertiary regional referral center for diabetes. In this 
single-center retrospective clinical observation, we included 
all consecutive women with pre-existing T1DM who were 
registered between the years 2016 and 2017, and their 
data was collected at the time of the first antenatal visit. All 
participants were Caucasians and residents of southeastern 
Poland. Data from their medical records including preges-
tational and clinical data were collected during the first 
pregnancy visit, as described earlier [3, 12]. We included all 
consecutive women diagnosed with T1DM at least one year 
before conception. The study participants were followed 
during their pregnancy and up to 3-6 months postpartum 
through the end of 2018. T1DM was diagnosed based on 
the World Health Organization criteria and acute onset with 
typical symptoms, ketosis or ketoacidosis at the time of 
diagnosis and insulin dependence from the onset. Autoan-
tibodies were not routinely tested and were not required 
for a T1DM diagnosis.
Pregnant or pregnancy planning women received an in-
tensive diabetes management program, which involved 
education on diet, physical activity, glycemic goals, SMBG 
(self-monitoring of blood glucose), frequent outpatient vis-
its, and if necessary, hospital admission. The educational 
program was adjusted for the appropriate insulin treat-
ment regimen: multiple daily injections (MDI) or CSII with 
a personal insulin pump. Whenever CGM was available, its 
use was included in the education program. A woman with 
T1DM referred to the center before conception was consid-
ered pregnancy planning. If the first visit was registered after 
conception, such a pregnancy was considered not planned. 
According to the guidelines of the Polish Diabetes Asso-
ciation, the target HbA1c was < 6.0%, self-monitored glucose 
3.9–5.0 mmol/L (70–90 mg/dL) at fasting states, < 6.7 mmol/L 
(< 120 mg/dL) 60 minutes after meals and > 3.3 mmol/L (> 
60 mg/dL) between 2 and 4 am [13]. In 2017, the targets were 
changed to HbA1c < 6.5% in 1
st trimester and < 6.0% in 2nd 
and 3rd trimester, self-monitored glucose 3.9–5.0 mmol/L 
(70–90 mg/dL) at fasting states, < 7.8 mmol/L (< 140 mg/dL) 
60 minutes after meals and 3.9–5.0 mmol/L (70–90 mg/dL) 
between 2 and 4 am [14]. All women had diabetes and 
control obstetric visits every four weeks throughout the 
pregnancy. The recommended standard calorie intake was 
about 30–35 kcal/kg of body weight and depended on the 
body weight, height, physical activity and age [13]. The 
patients were advised to consume 40–50% of calories from 
carbohydrates, 20–30% from fats and 30% from proteins. The 
recommended weight gain depended on baseline body 
weight (11.3–15.9 kg for women with normal weight, 6.8–
11.4 kg for overweight women, 4.5–9.1 kg for women with 
obesity and up to 18 kg for patients with BMI < 19.8 kg/m2) 
[13–15]. Excess weight gain was managed by reducing food 
intake. Ketone levels were monitored daily from a morning 
urine sample. 
In the Clinical Department of Metabolic Diseases, there 
were insulin pumps available for rent to T1DM pregnant 
women or those who were planning a pregnancy. The in-
sulin pumps and sensors came from a donation program 
sponsored by “The Great Orchestra of Christmas Charity” 
Foundation (The Orchestra Foundation), one of the largest 
charities in Poland. The costs of the insulin pump and CGM 
are not reimbursed for patients under the age of 26 in Po-
land. The specialists in our out-patient clinic recommended 
and prescribed CSII or sensor-augmented insulin pump 
(SAP) therapy due to pregnancy or in women planning to 
become pregnant. Women in our study received personal 
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insulin pumps and CGM (transmitter and sensors) free of 
charge. There were two pump models: automatic insulin 
delivery suspension on low glucose level (SLG) — Para-
digm Veo or predictive low glucose suspend (PLGS) — Min-
iMed640G. Patients were strongly encouraged to use the 
CSII regimen as well as CGM during pregnancy, although 
this was limited due to patient compliance. The choice of 
insulin pump model, SLG or PLGS, was usually based on 
the current availability. The use of MDI was based on the 
patient’s personal preferences. 
We excluded from the current analysis women who 
experienced a miscarriage (before 22nd week of gestation, 
n = 6) or with incomplete follow-up data, specifically without 
a documented postnatal visit with a recorded gestational 
age and birth weight. Only singleton pregnancies were 
analyzed. The baseline characteristics were recorded at the 
first visit. They included age, T1DM duration, preconception 
body weight, body mass index (BMI), and the presence 
of diabetes complications such as retinopathy diagnosed 
by an ophthalmologist, decreased glomerular filtration or 
albuminuria. Every woman had their HbA1c level tested at 
the first, second and third trimester, as well as 3–6 months 
after delivery. In addition, the preconception HbA1c was 
also obtained either from the patient’s past medical records 
or it was measured during their pregnancy planning visit. 
The following endpoints were considered in the analysis: 
HbA1c level and its change throughout the pregnancy and 
after delivery, the maternal weight gain during pregnancy, 
the birth weight and the presence of macrosomia (> 4000 g) 
in term pregnancies, the low birth weight (< 2500 g), the 
frequency of preterm deliveries (< 37th week of gestation), 
the frequency of caesarean deliveries, infant deaths and 
congenital malformations. We searched for the association 
between these variables and the specific model of insulin 
therapy (the use of insulin pump with or without CGM or MDI 
regimen) as well as pregnancy planning. We were unable to 
assess the newer parameters of glucose control quality like 
time in range (TIR), time below range (TBR) and above range 
(TAB), glycaemic variability assessed by coefficient variation 
(%CV) and GMI (glucose management indicator) because 
only some of the patients used CGM [16].
The data is reported as counts and percentages for cat-
egorical variables or medians with quartiles for continuous 
variables (more appropriate for small samples). Propor-
tions were compared using the chi-squared test or Fisher 
exact test, when applicable. Differences between medians 
were compared using the Wilcoxon rank sum test. Shap-
iro-Wilk test was used to assess normality of the distribution. 
Bartlett’s test was used to assess homogeneity of varianc-
es. To compare the mean of more than two groups we used 
ANOVA test or Kruskal-Wallis rank sum test as nonparametric 
equivalent. The differences between mean levels of HbA1c 
were tested in a multiple repeated measures regression 
model that implemented an unstructured covariance matrix. 
Data analysis was performed in SAS 9.4. P-values < 0.05 were 
considered significant.
reSuLTS
We identified 109 women with T1DM referred to the 
Clinical Department for pregnancy planning or while preg-
nant. We excluded women who miscarried (n = 6), women 
who missed their post-delivery visit and those who’s out-
come data was missing (n = 22). In the analysis, we included 
81 singleton pregnancies. We were unable to analyze mis-
carriages as an outcome because the data was incomplete. 
There were 36 (44.4%) women planning to become 
pregnant. Most of these were treated with CSII before con-
ception and then during the pregnancy. Only six women 
were treated with an MDI regimen during the planning 
stage and three were then switched to CSII after conception. 
Conversely, 31 (68.9%) women who did not plan pregnancy 
were on an MDI regimen before conception. Most were 
then switched to CSII for the duration of the pregnancy. 
The insulin treatment and pregnancy planning are shown in 
detail in Table 1. During pregnancy, only 11 patients (13.6%) 
remained on an MDI regimen, while 70 (86.4%) were treated 
with CSII. There were 28 (40%) patients on insulin pumps 
who used CGM sensors. A pump with automatic PLGS was 
available to 13 CGM users. Subsequent comparisons are be-
tween MDI, CSII without CGM and CSII with CGM groups. As 
an auxiliary analysis, we report comparisons between CSII 
patients using CGM with and without automatic insulin 
delivery suspension feature implemented in Medtronic 
640G pump.
The clinical characteristics of the study participants are 
provided in Table 2. Briefly, the median age was 29 years and 
Table 1. Methods of insulin treatment before and during pregnancy in the study group
Treatment Planning, n = 36 (44.4%) not planning, n = 45 (55.6%)
Before pregnancy during pregnancy Before pregnancy during pregnancy
MDI, n (%) 6 (16.7) 3 (8.3) 31 (68.9%) 8 (17.8) 
CSII, n (%) 30 (83.3) 33 (91.7) 14 (31.1%) 37 (82.2)
MDI — multiple daily injections; CSII — continuous subcutaneous insulin infusion
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T1DM duration was 15 years, without clinically significant 
differences between the treatment groups. The distribution 
of White’s classes was not different (p-value for differences 
between treatments was 0.68). The patients before concep-
tion had predominantly normal body weight. The patients 
were characterized by well-controlled diabetes, with me-
dian HbA1c level before pregnancy (and before pregnancy 
planning) 6.5%. Differences between median baseline HbA1c 
among treatment groups were not statistically significant 
(p = 0.081).
Pregnancy planning was associated with HbA1c lower 
by 0.9% at the initial visit (p < 0.001) and in the first trimester 
(p < 0.001). The difference became small (0.1–0.3%) and not 
statistically significant in the second and third trimester or 
after delivery. To account for some of these imbalances in 
the frequency of pregnancy planning between treatment 
groups, especially in the MDI group, estimated mean levels 
of HbA1c in subsequent analyses are adjusted for pregnancy 
planning. The HbA1c levels throughout the pregnancy are 
shown and compared in Figure 1. On the first pregnancy 
visit, the women using sensors had already lower HbA1c, 
although the difference did not reach statistical significance 
(5.6% in CGM users vs 6.0% and 6.2% in CSII and MDI groups, 
respectively, p = 0.149). Women using CGM during preg-
nancy had the lowest HbA1c (5.3%, 5.3% and 5.2% in the 
1st, 2nd and 3rd trimester, respectively). After the pregnancy, 
the HbA1c increased to 5.5% within 3-6 months. In the CSII 
group not using CGM, HbA1c was 5.4%, 5.6% and 5.6% in 
the first, second and third trimester, respectively, increasing 
to 6.0% after the pregnancy ended. The highest HbA1c was 
Figure 1. HbA1c levels throughout pregnancy
Table 2. Clinical characteristics of the study cohort at baseline






(n = 11) p-value
Age (years), median (IQR) 29 (27, 33) 30 (27, 33) 28 (26, 33) 29 (27, 32) 0.314
Diabetes duration (years), median (IQR) 15 (9, 18) 13 (9, 19) 16 (10, 20) 12 (3, 17) 0.117
BMI before conception [kg/m2], median (IQR) 22.5 (21.0, 25.8) 21.9 (20.6, 24.5) 23.0 (21.8, 26.7) 22.9 (19.8, 24.6) 0.388
Systolic blood pressure [mm Hg], median (IQR) 125 (114, 135) 124 (110, 141) 127 (121, 134) 113 (106, 121) 0.069
Diastolic blood pressure [mm Hg], median (IQR) 74 (70, 80) 73 (66, 81) 75 (70, 80) 72 (70, 77) 0.770
Pre-conception HbA1c (%), median (IQR) 6.5 (6.1, 7.4) 6.2 (6.0, 7.1) 6.7 (6.2, 7.7) 6.4 (5.8, 8.0) 0.081
White’s class: B, n (%)
C, n (%)














Retinopathy, n (%) 17 (21.0) 5 (17.9) 11 (26.2) 1 (9.1) 0.590
Albuminuria, n (%) 3 (3.7) 1 (3.6) 2 (4.8) 0 1.000
Daily insulin dose before pregnancy (U), median (IQR) 45 (34, 54) 45 (37, 52) 44 (34, 51) 41 (34, 63) 0.677
Pregnancy planning, n (%) 36 (44.4) 12 (42.9) 21 (50.0) 3 (27.3) 0.931
BMI — body mass index; HbA1c — glycated hemoglobin A1c; IQR — interquartile range
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observed in the MDI group: 6.5%, 6.0% and 5.9% (1st, 2nd, 
3rd trimester) and 6.6% during the postpartum visit. The 
differences between the study groups were statistically sig-
nificant: p = 0.003, p = 0.030, p = 0.039 and p = 0.002 for the 
first, second and third trimesters, as well as post-pregnancy 
time points, respectively.
To further explore the impact of the use of CGM dur-
ing pregnancy, we compared patients who did not use 
CGM against patients using CGM with and without the 
automatic insulin delivery suspension. Although patients 
who received pumps with PLGS had numerically (but not 
significantly) higher HbA1c measured during the first visit 
(5.7%) than women using CSII without this function (5.3%), 
they achieved a significantly lower HbA1c (5.1%) than the 
other CSII patients using (5.3%) or not using (5.6%) CGM 
(p = 0.044) during the third trimester. The difference re-
mained significant after pregnancy (5.3%, 5.6% and 6.0%, 
respectively, p = 0.016).
Pregnancy outcomes are summarized in Table 3. We 
did not find any significant differences in the pregnancy 
duration, gestational age at delivery, birth weight (also in 
an analysis limited to term pregnancies) or macrosomia risk. 
A composite outcome of macrosomia and preterm birth, as 
a preterm birth may be considered a proxy of macrosomia, 
did not reach statistical significance (p = 0.23), although 
there was numerically lower risk of this outcome among pa-
tients that used CGM (28.6% versus 45.2% in pump users and 
54.5% in the MDI group). The risk of macrosomia in the study 
cohort was high, 19.7%, despite good glycemic control, es-
pecially in the third trimester. There were four (4.9%) cases 
of birth weight > 4,500 g. The risk of birth weight < 2,500 g 
was 7.4%, without significant differences between study 
groups. There were 58 caesarian sections (71.6%), with 
a significantly lower rate in the MDI group (36.4% versus 
69.1% in CGM non-users and 89.3% CGM users, respec-
tively, p = 0.004). We recorded eight congenital malforma-
tions. Among them there were five cases of congenital heart 
abnormalities- one case of patent foramen ovale, one case 
of atrioventricular septum defect and aortic coarctation 
associated with trisomy 21 and one case of benign right 
ventricular hypertrophy with mild stenosis of the pulmo-
nary valve, one case of ventricular septum defect and one 
case of Fallot’s tetralogy. Other congenital malformations 
concerned two genetically determined syndromes — a case 
of Beckwith-Wiedemann syndrome (BWS) characterized by 
an enlarged tongue, umbilical hernia, hyperplasia, neonatal 
hypoglycemia and a case of multiple birth defects including 
atresia of the pulmonary trunk, major aortopulmonary col-
lateral arteries (MAPCAS), ventricular septal defect, Fallot’s 
tetralogy. We recorded one case of congenital limb defect. 
All pregnancies with defects were unplanned. There were 
no stillbirths or early hospital deaths in the study group. 
We did not observe significant differences in birth weight 
or a macrosomia risk between CGM users with and without 
automatic insulin delivery suspension.
dISCuSSIOn
In our present study, we evaluated the role of CGM 
technology in the management of T1DM in women during 
pregnancy. We observed that the use of CGM was associated 
with lower HbA1c levels during pregnancy and this lasted 
for some time after delivery. In the third trimester, the dif-
ference in HbA1c level reached 0.4% between CSII-treated 
women using and not using CGM. The CGM users compared 
to women treated with MDI had a 0.7% lower HbA1c level. 
These results of using CGM during pregnancy in women 
with preexisting T1DM were comparable to some earlier 
published data [17]. It was described in an Irish cohort that 
CGM use was associated with improved glycemic control 
in the third trimester and lower birth weights and reduced 
risk of macrosomia. A separate observational study depicted 
a similar improvement of glycemic control parameters in 
Table 3. Pregnancy outcomes in the study group




(n = 11) p-value
Gestational age at delivery (years), median (IQR) 38 (38, 39) 38 (36, 39) 38 (35, 39) 0.156
Maternal weight gain [kg], median (IQR) 17 (13, 21) 16 (14, 18) 14 (11, 17) 0.239
Birth weight (g), median (IQR) 3535 (3245, 3965) 3580 (3160, 3800) 3250 (2700, 4100) 0.510
Birth weight in term pregnancies [g], median (IQR) 3585 (3300, 4000) 3730 (3340, 3940) 3515 (3195, 4135) 0.780
Preterm births, n (%) 2 (7.1) 12 (28.6) 3 (27.2) 0.084
Macrosomia (> 4,000 g), n (%) 6 (21.4) 7 (16.7) 3 (27.2) 0.710
Low birth weight (< 2,500 g), n (%) 1 (3.6) 3 (7.1) 2 (18.2) 0.276
Caesarian section, n (%) 25 (89.3) 29 (69.1) 4 (36.4) 0.004*
Birth defect, n (%) 3 (10.7) 3 (7.1) 1 (9.1) 0.870
*???
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pregnant women with diabetes due to the use of CGM 
[18]. We also observed that pumps augmented with CGM 
with PLGS seemed to help women to achieve even better 
glycemic control as assessed by HbA1c.
 In the third trimester, the difference in HbA1c between 
PLGS pump users and the users of other pumps with CGM 
was 0.2% lower for PLGS users as compared to MDI and not 
CGM users. Similarly, to a recently published study, we have 
also shown a favorable reduction in HbA1c levels when using 
an insulin pump compared to MDI [19]. We were unable to 
demonstrate a reduction in glycemic variability because the 
CGM was not used in the whole observed group.
With this limited sample size, we were unable to detect 
significant differences in maternal or fetal complications of 
pregnancy. Despite a very good glycemic control, the risk 
of macrosomia (> 4,000 g) remained high reaching 19.7%. 
No significant differences were seen in the risk of this com-
plication between the study groups.
The current findings are concordant with our previous 
publications [3, 12]. We were able to confirm that pregnan-
cy planning leads to better glycemic control throughout 
the pregnancy regardless of the insulin treatment regimen. 
We also noted a similar risk of macrosomia (19,7%), as in our 
previous publication (22.7%). It is unfortunate that despite 
technological improvements and strict standards of care, 
one in five pregnancies of women with T1DM results in 
the delivery of a macrosomic baby. Similar results were 
observed in an observational German study; they showed 
higher rates of large-for-gestational-age (LGA) neonates in 
the CSII-treated group vs MDI- treated group of pregnant 
women with T1DM, possibly mediated by excess maternal 
weight gain, which occurred more frequently in CSII us-
ers [20]. 
The recent results of CONCEPTT trial indicate that CGM 
use is associated with a statistically significant, but relatively 
small improvement in HbA1c level. It has also been shown 
to improve the time in range spent on the glycemic target 
[9]. CGM use was associated with a reduced risk of macro-
somia, shorter hospitalization, less neonatal intensive care 
admissions and a lower risk of neonatal hypoglycemia. The 
widespread use of CGM during pregnancy may induce cost 
savings in the healthcare system due to the reduced risk 
of hyperglycemic-related complications. Women enrolled 
in the trial were characterized by a higher preconception 
HbA1c, as well as HbA1c during pregnancy. Similar levels of 
HbA1c were recorded in an observational study in Sweden 
[21], which compared a real-time and intermittent CGM 
during pregnancy. In our study, HbA1c declined to levels 
typically observed in non-diabetic individuals during the 
second and third trimesters. This may explain the lower risk 
of macrosomia observed in our study and a small number 
of cases of birth weight exceeding 4.5 kg. 
In this study, we attempted to compare the use of pumps 
augmented with CGM versus the use of pumps without CGM 
and MDI regimen. The observational study design does not 
allow for any firm conclusions, however, there was a clear 
trend towards better glycemic control among the users of 
insulin pumps with CGM. 
There were several limitations in our study that need 
to be acknowledged. First, the time frame of the study and 
its sample size is limited. Subsequently, we were not able 
to perform a regression analysis for important pregnancy 
outcomes, such as birth weight. The study lacked power 
to detect differences in infrequent complications such as 
congenital malformations or deaths. Treatment allocation 
was not randomized, and in the case of an MDI regimen, it 
was specifically provided to women not accepting CSII for 
various reasons. Such a study may be considered a hypoth-
esis-generating one rather than providing definitive conclu-
sions. Nevertheless, reporting real-world data, such as this 
and related to the important problems of T1DM complicated 
pregnancy, supplements the results of randomized clinical 
trials. Another limitation of the study was the inability to 
compare modern glycemic control parameters. 
COnCLuSIOnS 
In summary, the use of pumps integrated with CGM 
may improve glycemic control as estimated with HbA1c. 
Despite the use of a new generation of treatment, the pro-
portion of macrosomia remains high in T1DM complicated 
pregnancies. 
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